FDA expands indication for Genentech cancer drug
Herceptin will be combined with doxorubicin, cyclophosphamide and paclitaxel to treat HER-2 positive early-stage breast cancer patients who have had initial treatment with the goal of reducing the
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).